CMEA Ventures Into Development, But Not Tied To Lilly As Expected
By
Alex Lash / Email the Author / “The Pink Sheet” Jun. 27, 2011, Vol. 73, No. 26
Business & Finance / Word Count: 763 / Article # 00110627023
Executive Summary
Several biopharma venture investors are experimenting with new models to avoid the long timelines and massive pay checks typically required to nurture new biotech companies. One of those investors, CMEA Capital of San Francisco, officially debuted its model Thursday, June 23, but not before making a major strategic shift.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.